Optimal Dose of Combination of Rocuronium and Cisatracurium

Anesthesia Clinical Trial

— CRC  

Official title:

Optimal Dose of Combination of Rocuronium and Cisatracurium: A Randomized Double-blinded Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02495038
• Other study ID #: combination P-1
• Status: Completed
• Phase: N/A
• First received: June 4, 2015
• Last updated: January 31, 2018
• Start date: March 2014
• Est. completion date: February 2015

Study information

• Verified date: January 2018
• Source: Yonsei University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

BACKGROUND: The combinations of rocuronium and cisatracurium have a synergic effect. The investigators studied whether the prediction is possible to have a sufficient effect of reducing the dose when combining the two neuromuscular blocking agents through monitoring neuromuscular relaxation during surgery.

METHODS: Each group were intubating dose group (Group I, n=27) combined Effective Dose (ED)95 rocuronium and ED95 cisatracurium, small amount reducing group (Group S, n=27) reduced 10% of each ED95 and large amount reducing group (Group L, n=27) reduced 20% of each ED95. Before patients arrived in the operating room, rocuronium and cisatracurium were prepared by a nurse who was not involved in this study. Each study drug was administrated to the patient and timer was started with TOF-Watch® monitoring. Train-of-four (TOF) of the ulnar nerve was used as setting of 2 Hz per 12 sec. The investigators checked time to TOF ratio=0 (Onset), time to 1st TOF ratio>25% (Duration 25%) and TOF 25-75% (recovery index) under total i.v. anesthesia (TIVA). One way ANOVA was used for statistical analysis (α=0.05, β=0.2).

Description:

Introduction:

Rocuronium and cisatracurium are representative neuromuscular blocking agents used widely because the former have features of fast onset of peak effect and short duration of muscle relaxation relatively while the latter have comparatively long duration relaxation time and break down by Hofmann elimination and ester hydrolysis. A combination of the two have a synergic effect may be also used with either the priming method for rapid sequence intubation. It would contribute both to determine the effective combination rate clinically and to predict the pharmacokinetic characteristics that determine how much the synergistic effect of this combination. The investigators studied whether the prediction is possible to have a sufficient effect of reducing the dose when combining the two muscle relaxants through monitoring muscle relaxation during surgery.

Materials and methods:

This study was conducted to 81 patients scheduled for elective mastoidectomy and tympanoplasty after obtaining written informed consent. All patients included the American Society of Anesthesiologists (ASA) physical status I-II, aged 20-60, BMI 20-30 kg/m2. The exclusion criteria were as follows: a history of allergy to the study drugs, neuromuscular disease, pregnancy or breast-feeding, preoperative medication of antipsychotics or neuroleptics known to interact with non-depolarizing neuromuscular blocking agents (NMBAs), serum creatinine level>1.2 mg/dL, liver transaminase>40 U/L. Anthropometric variables such as height, weight were measured in ward before surgery. BMI calculated as total body weight divided by the squared height. Ideal body weight (IBW) was calculated by the formula of Devine {50 kg + 2.3 × (height [inch]-60) for man and 45.5 kg + 2.3 × (height [inch]-60) for woman} and used to administrate NMBAs of initial dose. Lean body weight (LBW) was calculated by the formula of James {LBW (men) = (1.10 × Weight(kg)) - 128 × ( Weight2 / (100 × Height(m))2), (women) = (1.07 × Weight(kg)) - 148 × ( Weight2 / (100 × Height(m))2)}. Additive dose of NMBAs was administrated by LBW. Patients were randomly assigned to each group by opening of sealed allocation envelope. Each group were intubating dose group (Group I, n=27) combined ED95 rocuronium and ED95 cisatracurium, small amount reducing group (Group S, n=27) reduced 10% of each ED95 and large amount reducing group (Group L, n=27) reduced 20% of each ED95.

Monitoring and Medication:

In the operating room, monitoring was accomplished to patients with a noninvasive blood pressure, pulse oximetry, electrocardiography, thermometer, Bispectral Index (BIS VISTA Monitoring System; Aspect Medical Systems Inc, Norwood, MA, USA), and T1/T4 ratio used TOF-Watch® (Organon, Teknica B.V., Boxtel, the Netherlands). Every 5 min, measured things are recorded.

Premedications with midazolam 2 mg and glycopyrrolate 0.2 mg were administrated to patients intramuscularly 1 h before surgery. Before patients arrived in the operating room, rocuronium and cisatracurium were prepared by a nurse who was not involved in this study. The syringe containing each study drug was conveyed to the performer of this study as the status of shielding the scale. The syringes of rocuronium and cisatracurium used each other syringe. Anesthesia was induced with propofol 1.5-2.5 mg/kg, remifentanil 0.4-0.6 mcg/kg, afterward maintained with target controlled infusion (TCI) of propofol 5-10 mg/kg/hr and remifentanil 0.05-2 mcg/kg/min. The infusion pump (Orchestra Module DPS, Fresenius-Vial, Brezins, France) was operated with Minto's and Marshall's pharmacokinetic model for effect site TCI of remifentanil and propofol.

The opposite arm against operation side was used for neuromuscular monitoring and attached to armboard of TOF-Watch®. Each study drug was administrated to the patient and timer was started with T1/T4 ratio monitoring. The surface electrodes of ulnar nerve placed at the wrist and Train-of-four (TOF) stimulation was used as setting of supramaximal square wave impulses with 200μs duration, 2 Hz per 12sec. The investigators checked times to TOF ratio=0 (Onset), 1st TOF ratio>25% (Duration 25%) and TOF 25-75% (Recovery Index), recovery time of 90% (TOF 25-90%) under total i.v. anesthesia (TIVA). Also the investigators checked the rate of additional rescue dose administrated with 10% of initial NMBAs dose, operation time from incision to surgical wound dressing, anesthesia time from entering to going out the operation room. Body temperature was maintained above 35°C using warm air blanket. The arterial pressure cuff was placed on the opposite arm against TOF monitoring.

Adverse Events and Management:

In all patients, anesthesia level was assessed based on a BIS score of 40-60. Moderate hypertension (>120% of baseline) or hypotension (<80% of baseline) was treated by increasing or decreasing rate of propofol infusion with fluid supplement. Severe hemodynamic change (systolic pressure < 90 mmHg or > 200 mmHg) was controlled by intravenous (IV) administration of phenylephrine 50 mcg or nicardipine 250 mcg repeatedly until being hemodynamic stable status. Unexpectedly, when hiccup or self-contained respiration was showed, additional rescue dose of NMBAs was administrated to the patient even though T1/T4 ratio was lower than 25%.

Statistical Analysis:

All data are expressed as means ± standard deviations (SDs), numbers (percentages), or medians (upper and lower quartiles), as appropriate. Data between the groups were compared using the χ2 test, Fisher exact test, independent t test, or the Mann-Whitney U test, as appropriate. To assess data normality, the Kolmogorov-Smirnov test was performed on the data set. According to a preliminary study, 24 patients would be required in each group with a power of 0.9 and a type I error of 0.05. Factoring in a drop-out rate of 10%, the investigators calculated that 27 patients would be required for each group. All statistical analyses were performed with the SPSS 18.0 (SPSS Inc., Chicago, IL, USA) program. A P value <0.05 was considered statistically significant.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 81
• Est. completion date: February 2015
• Est. primary completion date: February 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 60 Years

Eligibility

Inclusion Criteria:

• the American Society of Anesthesiologists (ASA) physical status I-II

• BMI 20-30 kg/m2

• Patients scheduled for mastoidectomy and tympanoplasty.

Exclusion Criteria:

• a history of allergy to the study drugs,

• neuromuscular disease,

• pregnancy

• breast-feeding,

• preoperative medication of antipsychotics or neuroleptics known to interact with NMBAs

• serum creatinine level>1.2 mg/dL,

• liver transaminase>40 U/L.

Related Conditions & MeSH terms

• Anesthesia
• Chronic Otitis Media
• Otitis Media

Intervention

Drug:
• 10% reduction of combination of Esmeron® and Nimbex®
Patients were randomly assigned to each group by opening of sealed allocation envelope. After collection of data, allocation number was matched with each group. The participants matched at Group S were administered with NMBAs reduced 10% of each ED95. Before patients arrived in the operating room, rocuronium and cisatracurium were prepared by a nurse who was not involved in this study. Each drug dosage was determined by allocation number. The syringe containing each study drug was conveyed to the performer of this study as the status of shielding the scale. The syringes of rocuronium and cisatracurium used each other syringe.
• 20% reduction of combination of Esmeron® and Nimbex®
The participants matched at Group L were administered with NMBAs reduced 20% of each ED95.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Yonsei University

References & Publications (22)

Adamus M, Gabrhelik T, Marek O. Influence of gender on the course of neuromuscular block following a single bolus dose of cisatracurium or rocuronium. Eur J Anaesthesiol. 2008 Jul;25(7):589-95. doi: 10.1017/S026502150800402X. Epub 2008 Apr 11. — View Citation

Amin AM, Mohammad MY, Ibrahim MF. Comparative study of neuromuscular blocking and hemodynamic effects of rocuronium and cisatracurium under sevoflurane or total intravenous anesthesia. Middle East J Anaesthesiol. 2009 Feb;20(1):39-51. — View Citation

Breslin DS, Jiao K, Habib AS, Schultz J, Gan TJ. Pharmacodynamic interactions between cisatracurium and rocuronium. Anesth Analg. 2004 Jan;98(1):107-10, table of contents. — View Citation

Cammu G, de Baerdemaeker L, den Blauwen N, de Mey JC, Struys M, Mortier E. Postoperative residual curarization with cisatracurium and rocuronium infusions. Eur J Anaesthesiol. 2002 Feb;19(2):129-34. — View Citation

de Morais BS, de Castro CH, Teixeira VC, Pinto AS. Residual neuromuscular block after rocuronium or cisatracurium. Rev Bras Anestesiol. 2005 Dec;55(6):622-30. English, Portuguese. — View Citation

Donati F, Plaud B. Rocuronium-cisatracurium combinations. Anesthesiology. 1999 Aug;91(2):587-8. — View Citation

Fassbender P, Geldner G, Blobner M, Hofmockel R, Rex C, Gautam S, Malhotra A, Eikermann M. Clinical predictors of duration of action of cisatracurium and rocuronium administered long-term. Am J Crit Care. 2009 Sep;18(5):439-45. doi: 10.4037/ajcc2009883. — View Citation

Flockton EA, Mastronardi P, Hunter JM, Gomar C, Mirakhur RK, Aguilera L, Giunta FG, Meistelman C, Prins ME. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth. 2008 May;100(5):622-30. doi: 10.1093/bja/aen037. Epub 2008 Apr 2. — View Citation

Hans P, Welter P, Dewandre PY, Brichant JF, Bonhomme V. Recovery from neuromuscular block after an intubation dose of cisatracurium and rocuronium in lumbar disc surgery. Acta Anaesthesiol Belg. 2004;55(2):129-33. — View Citation

Kim KS, Chun YS, Chon SU, Suh JK. Neuromuscular interaction between cisatracurium and mivacurium, atracurium, vecuronium or rocuronium administered in combination. Anaesthesia. 1998 Sep;53(9):872-8. — View Citation

Kopman AF, Kopman DJ, Ng J, Zank LM. Antagonism of profound cisatracurium and rocuronium block: the role of objective assessment of neuromuscular function. J Clin Anesth. 2005 Feb;17(1):30-5. — View Citation

Kopman AF, Zank LM, Ng J, Neuman GG. Antagonism of cisatracurium and rocuronium block at a tactile train-of-four count of 2: should quantitative assessment of neuromuscular function be mandatory? Anesth Analg. 2004 Jan;98(1):102-6, table of contents. — View Citation

Lee H, Jeong S, Choi C, Jeong H, Lee S, Jeong S. Anesthesiologist's satisfaction using between cisatracurium and rocuronium for the intubation in the anesthesia induced by remifentanil and propofol. Korean J Anesthesiol. 2013 Jan;64(1):34-9. doi: 10.4097/kjae.2013.64.1.34. Epub 2013 Jan 21. — View Citation

Leykin Y, Pellis T, Lucca M, Gullo A. Intubation conditions following rocuronium: influence of induction agent and priming. Anaesth Intensive Care. 2005 Aug;33(4):462-8. — View Citation

Leykin Y, Pellis T, Lucca M, Lomangino G, Marzano B, Gullo A. The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients. Anesth Analg. 2004 Oct;99(4):1086-9, table of contents. — View Citation

Lighthall GK, Jamieson MA, Katolik J, Brock-Utne JG. A comparison of the onset and clinical duration of high doses of cisatracurium and rocuronium. J Clin Anesth. 1999 May;11(3):220-5. — View Citation

Lin SP, Chang KY, Chen YJ, Lin SM, Chang WK, Chan KH, Ting CK. Priming with rocuronium to accelerate the onset time of cisatracurium during intubation. J Chin Med Assoc. 2009 Jan;72(1):15-9. doi: 10.1016/S1726-4901(09)70014-0. — View Citation

Liu M, Dilger JP. Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33. doi: 10.1213/ane.0b013e31817b4469. — View Citation

Mak PH, Irwin MG. The effect of cisatracurium and rocuronium on cisatracurium precurarization and the priming principle. J Clin Anesth. 2004 Mar;16(2):83-7. — View Citation

Miller DR, Wherrett C, Hull K, Watson J, Legault S. Cumulation characteristics of cisatracurium and rocuronium during continuous infusion. Can J Anaesth. 2000 Oct;47(10):943-9. — View Citation

Naguib M, Samarkandi AH, Ammar A, Elfaqih SR, Al-Zahrani S, Turkistani A. Comparative clinical pharmacology of rocuronium, cisatracurium, and their combination. Anesthesiology. 1998 Nov;89(5):1116-24. Erratum in: Anesthesiology 1999 Apr;90(4):1241. — View Citation

Zeidan A, Nahle N, Maaliki H, Baraka A. Cisatracurium or rocuronium versus rocuronium-cisatracurium combination. Middle East J Anaesthesiol. 2006 Jun;18(5):879-86. — View Citation

* Note: There are 22 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Non Invasive Blood Pressure,	Before induction of anesthesia, non invasive blood pressure was measured for baseline.; And after injection of NMBAs, non invasive blood pressure was measured at 10 min.	Before and after induction of anesthesia, an average 10 min.
Other	Peripheral Oxygen Saturation	Before induction of anesthesia, peripheral oxygen saturation was measured for baseline.; And after injection of NMBAs, peripheral oxygen saturation was measured at 10 min.	Before and after induction of anesthesia, an average 10 min.
Other	Body Temperature	Before induction of anesthesia, body temperature was measured for baseline by oral temperature probe.; And after injection of NMBAs, non invasive blood pressure was measured at 10 min by esophageal temperature probe.	Before and after induction of anesthesia, an average 10 min.
Other	Bispectral Index	The BIS monitor provides a single dimensionless number, which ranges from 0 (equivalent to EEG silence) to 100. A BIS value between 40 and 60 indicates an appropriate level for general anesthesia, as recommended by the manufacturer.; Before induction of anesthesia, bispectral index was measured for baseline. And after injection of NMBAs, bispectral index was measured at 10 min.	Before and after induction of anesthesia, an average 10 min.
Primary	Onset of Neuromuscular Blocking Agents(NMBAs)	Time from administration of initial NMBAs to Train-of-four (TOF) ratio=0, assessed up to 15 minutes during general anesthesia.	Intraoperative, an average of 5 minutes
Primary	Duration 25% of Neuromuscular Blocking Agents(NMBAs)	Time from administration of initial NMBAs to Train-of-four (TOF) ratio >25%, assessed up to 2 hours during general anesthesia.	Intraoperative, an average of 1 hours
Primary	Recovery Index of Neuromuscular Blocking Agents(NMBAs)	Time from TOF ratio 25% to 75%, assessed up to 1 hour during general anesthesia.	Intraoperative, an average of 20 minutes
Secondary	Operation Time	Time from skin incision to wound dressing assessed up to 8 hours.	Intraoperative, an average of 3 hours.
Secondary	Anesthetic Time	Time from induction to recovery of anesthesia, asessed up to 3 hours.	Intraoperative, an average 4 hours.
Secondary	Additional Rescue Doses Per Hour Ratio.	Additional Rescue Doses Per Hour Ratio is the number per hour of addition of rescue dose administrated with 10% of initial NMBAs dose. The formula is {(Addition number + 1 / Anesthetic time) x 60}.	Intraoperative, an average of 3 hours.